ANXA2 and hepatocellular carcinoma: Overall, ANXA2 is overexpressed in acute lymphoblastic leukemia (ALL) [57], APL [58], breast cancer [59], colorectal carcinoma (CRC) [60], gastric cancer [61], glioma [62], hepatocellular carcinoma (HCC) [63], lung cancer [31, 64, 65], multiple myeloma (MM) [66], oral squamous cell carcinoma (OSCC) [67], and pancreatic cancer [68, 69].